PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$25.16 USD
-0.13 (-0.51%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $25.19 +0.03 (0.12%) 5:04 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
PTCT 25.16 -0.13(-0.51%)
Will PTCT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTCT
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
Wall Street's Insights Into Key Metrics Ahead of PTC Therapeutics (PTCT) Q4 Earnings
Other News for PTCT
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA